ONIVYDE label
「ONIVYDE label」熱門搜尋資訊
「ONIVYDE label」文章包含有：「highlightsofprescribinginformation」、「ONIVYDE(irinotecanliposomeinjection)」、「Onivydepegylatedliposomal(previouslyknownasOnivyde)」、「ONIVYDEPEGYLATEDLIPOSOMAL」、「ONIVYDE-irinotecanhydrochlorideinjection」、「ONIVYDE」、「ONIVYDE®(irinotecanliposomeinjection)」、「ReferenceID」、「安能得®ONIVYDE®」
查看更多
highlights of prescribing information
https://www.ipsen.com
open-label trial. Protocol-specified therapy consisted of ONIVYDE 70 mg/m2 ... receiving ONIVYDE or ONIVYDE/5-FU/LV. Laboratory abnormalities that occurred ...
ONIVYDE (irinotecan liposome injection)
https://www.accessdata.fda.gov
The efficacy of ONIVYDE was evaluated in Study 1, a three-arm, randomized, open-label trial in patients with metastatic pancreatic adenocarcinoma with ...
Onivyde pegylated liposomal (previously known as Onivyde)
https://www.ema.europa.eu
Onivyde pegylated liposomal is a cancer medicine that is used to treat a form of pancreatic cancer called metastatic adenocarcinoma of the pancreas. Metastatic ...
ONIVYDE PEGYLATED LIPOSOMAL
https://www.ema.europa.eu
The safety and efficacy of ONIVYDE pegylated liposomal were investigated in a multinational, randomised, open label, controlled clinical study (NAPOLI–1) ...
ONIVYDE- irinotecan hydrochloride injection
https://dailymed.nlm.nih.gov
The ONIVYDE dose of 70 mg/m2 is based on irinotecan free base (equivalent to 80 mg/m2 of irinotecan as the hydrochloride trihydrate). Patients randomized to ...
ONIVYDE
https://www.ipsen.com
The efficacy of ONIVYDE was evaluated in Study 1, a three-arm, randomized, open-label trial in patients with metastatic pancreatic adenocarcinoma with ...
ONIVYDE® (irinotecan liposome injection)
https://www.onivyde.com
ONIVYDE® (irinotecan liposome injection) + 5-FU/LV is the #1 prescribed and only FDA-approved metastatic pancreatic cancer treatment post-gemcitabine.
Reference ID
https://www.accessdata.fda.gov
The efficacy of ONIVYDE was evaluated in Study 1, a three-arm, randomized, open-label trial in patients with metastatic pancreatic adenocarcinoma with ...
安能得® ONIVYDE®
https://www.pharmaengine.com
... LABEL, PHASE 3 TRIAL, The Lancet, 2023; 10409: 1272-1281. Zev A Wainberg, MD, Davide Melisi, MD, Teresa Marcarulla, MD, Roberto Pazo Cid, MD, Sreenivasa R ...